1. Home
  2. SG vs STTK Comparison

SG vs STTK Comparison

Compare SG & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sweetgreen Inc.

SG

Sweetgreen Inc.

HOLD

Current Price

$8.97

Market Cap

640.3M

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$4.95

Market Cap

538.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SG
STTK
Founded
2007
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
640.3M
538.3M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
SG
STTK
Price
$8.97
$4.95
Analyst Decision
Hold
Buy
Analyst Count
15
7
Target Price
$8.43
$10.00
AVG Volume (30 Days)
5.7M
989.6K
Earning Date
05-07-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.02
EPS
1.05
N/A
Revenue
$679,474,000.00
$1,000,000.00
Revenue This Year
$7.60
N/A
Revenue Next Year
$8.45
N/A
P/E Ratio
$8.52
N/A
Revenue Growth
0.39
N/A
52 Week Low
$4.49
$0.71
52 Week High
$16.70
$8.33

Technical Indicators

Market Signals
Indicator
SG
STTK
Relative Strength Index (RSI) 56.54 45.97
Support Level $6.39 $3.37
Resistance Level $9.14 $6.81
Average True Range (ATR) 0.75 0.58
MACD -0.02 0.06
Stochastic Oscillator 57.24 60.79

Price Performance

Historical Comparison
SG
STTK

About SG Sweetgreen Inc.

Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing. Its menu involves, Kids' meal, salads, sides, local items, Protein Plates, Desserts, Drinks and Others.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: